Effects of intravenous immunoglobulins on peripheral blood mononuclear cell activation in Vitro

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 694-708

  Sticherling, Michael ^a   Trawinski, Henning ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cytokine production; IL 2; In vitro proliferation; Intravenous immunoglobulins; Peripheral blood mononuclear cells; Phytohemagglutinin; Tetanus toxoid

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; TETANUS TOXOID;

AUTOIMMUNE DISEASE; CELL PROLIFERATION; CHEMICAL ANALYSIS; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; SECRETORY CELL;

EID: 35748970479     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.072     Document Type: Conference Paper

References (53)

1. KAZATCHKINE, M.D. & S.V. KAVERI. 2001. Immunmodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
2. JOLLES, S., W.A. SEWELL & S.A. MISBAH. 2005. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol. 142: 1-11.
3. BAYRY, J. et al. 2003. Mechanism of action of intravenous immunoglobulins in autoimmune and inflammatory diseases. Transfus. Clin. Biol. 10: 165-169.
4. BALLOW, M. 2005. Clinical and investigational considerations for the use of IGIV therapy. Am. J. Health Syst. Pharm. 62: S19-21.
5. SACHER, A.S. 2001. Intravenous immunoglobulin consensus statement. J. Allergy Clin. Immunol. 108: 139-145.
6. MONTANARO, A. & B. PIROFSKY. 1984. Prolonged interval high dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am. J. Med. 76: 67-72.
7. RAND, K.H. et al. 1991. Pharmacokinetics of intravenousimmunoglobulin. (Gammagard) in bone marrow transplantation. J. Clin. Pharmacol. 31: 1151-1154.
8. OCHS, H.D. et al. 1984. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am. J. Med. 76: 78-82.
9. KAVERI, S.V., G. DIETRICH & M.D. KAZATCHKINE. 1992. Can intravenous immunoglobulin treatment regulate autoimmune responses? Semin. Hematol. 29: 64-71.
10. HUREZ, V. et al. 1994. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg). Ther. Immunol. 1: 269-277.
11. SCHLUTER, S.F. et al. 2003. Natural autoantibodies to TCR public idiotypes: potential roles in immunomodulation. Cell. Mol. Biol. 49: 193-207.
12. LAKE, D.F. et al. 1995. Characterization of autoantibodies directed against T cell receptors. Adv. Exp. Med. Biol. 383: 223-229.
13. DEMETRIOU, M. et al. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409: 733-739.
14. CRUMPTON, M.J. et al. 1975. Recognition at cell surfaces: phytohaemagglutinin-lymphocyte interaction. Philos. Trans. R. Soc. Lond. B 272: 173-180.
15. PEROLA, O., A. RIPATTI & J. PELKONEN. 2000. T-lymphocyte subpopulations do not express identical combinations of interleukin-2 receptor chains in the early phase of their activation and proliferation. Scand. J. Immunol. 52: 123-130.
16. SERETI, I. et al. 2000. Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigen stimulation. Clin. Immunol. 97: 266-276.
17. VAN SCHAIK, N. et al. 1992. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J. Clin. Immunol.12: 325-334.
18. LEE, K.Y. et al. 2001. Varying effects of intravenous immunoglobulin on mononuclear cell proliferation in vitro. J. Korean Med. Sci. 16: 544-548.
19. ALDER, L.B.A., L.A. MORGAN & G.P. SPICKETT. 1996. Contribution of stabilizing agents present in intravenous immunoglobulin preparations to modulation of mononuclear cell proliferation in vitro. Scand. J. Immunol. 44: 585-591.
20. EIERMANN, T.H. et al. 2001. The effect of IgM-enriched human Ig and rabbit antithymocyte globulin on the stimulation of mononuclear cells. Scand. J. Immunol. 54: 626-629.
21. SBRANA, S. et al. 1993. In vitro effects of an immunoglobulin preparation for intravenous use (IVIG) on T-cells activation. Allerg. Immunol. 25: 35-37.
22. ANDERSSON, J. et al. 1996. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin. Exp. Immunol. 104: 10-20.
23. ANDERSSON, U. et al. 1994. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev. 139: 21-42.
24. SKANSÉN-SAPHIR, U. et al. 1998. Down-regulation of lymphokine synthesis by intravenous gammaglobulin is dependent upon accessory cells. Scand. J. Immunol. 47: 229-235.
25. NACHBAUR, D. et al. 1997. A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab′)2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 90: 212-218.
26. TAKEI, S., Y.K. ARORA & S.M. WALKER. 1993. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91: 602-607.
27. MODIANO, J.F. et al. 1997. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin. Immunol. Immunopathol. 83: 77-85.
28. KAWADA, K. & P.I. TERASAKI. 1987. Evidence of immunosuppression by high-dose gammaglobulin. Exp. Hematol. 15: 133-136.
29. SCHANZ, U., T. HÜGLE & J. GMÜR. 1996. Additional inhibitory effects of intravenous immunoglobulins in combination with cyclosporine A on human T lymphocyte alloproliferative response in vitro. Transplantation 61: 1736-1740.
30. NACHBAUR, D. et al. 1998. Modulation of alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin). Immunology 94: 279-283.
31. TOYODA, M. et al. 2004. Immunomodulatory effects of combination of pooled gammaglobulin and Rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 78: 1134-1138.
32. ACHIRON, A. et al. 1994. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. J. Clin. Invest. 93: 600-605.
33. PASHOV, A. et al. 1997. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulin (IVIg). Mult. Sklerose 3: 153-156.
34. BAYRY, J. et al. 2003. Inhibition of maturation and function of dentritic cells by intravenous immunoglobulins. Blood 101: 758-765.
35. BAYRY, J. et al. 2004. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 101: 14210-15215.
36. NIEDERBERGER, N. et al. 2005. Thymocyte stimulation by anti-TCR-(beta), but not by anti-TCR-(alpha), leads to induction of developmental transcription program. J. Leukoc. Biol. 77: 830-41.
37. IBANEZ, C. et al. 2005. Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia. Bio-Drugs 19: 59-65.
38. AUKRUST, P. et al. 1999. Administration of intravenous immunoglobulin (IVIG) in vivo - regulatory effects on the IL-1 system. Clin. Exp. Immunol. 115: 136-143.
39. REINHOLD, D. et al. 2004. Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (i.v. IG) in patients with multiple sclerosis. J. Neuroimmunol. 152: 191-194.
40. KRAUSE, I. & Y SHOENFELD. 2005. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis and malignant conditions. Methods Mol. Med. 109: 403-408.
41. BARCY, S. et al. 1995. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Int. Immunol. 7: 179-189.
42. ABE, Y. et al. 1994. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol. Rev. 139: 5-19.
43. STOHL, W. 1986. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J. Immunol. 136: 4407-4413.
44. KONDO, N. et al. 1991. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulines. J. Clin. Immunol. 11: 152-158.
45. KLAESSON, S. et al. 1993. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand. J. Immunol. 38: 477-484.
46. JUNGI, T.W. et al. 1986. Effect of various treatments of gammaglobulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang. 51: 18-26.
47. AKTAS, O. et al. 2001. Polyspecific immunoglobulins (IVIG) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J. Neuroimmun. 114: 160-167.
48. PRASAD, N.K.A. et al. 1998. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J. Immunol. 161: 3781-3790.
49. MOUTSCHEN, M.P., A.J. SCHEEN & P.J. LEFEBRE. 1992. Impaired immune response in diabetes mellitus: Analysis of the factors and mechanisms involved: relevance to the increase susceptibility of diabetic patients to specific infection. Diabetes Metab. 18: 187-201.
50. CAMPBELL, D.E., G.M. GEORGIOU & A.S. KEMP. 1999. Pooled human immunoglobulin inhibits IL-4 but not IFN-γ or TNF-α secretion following in vitro stimulation of mononuclear cells with staphylococcal superantigen. Cytokine 11: 359-365.
51. SEWELL, W.A.C. et al. 1999. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin. Exp. Immunol. 116: 509-515.
52. WU, K.H. et al. 2006. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr. Allergy Immunol. 17: 60-68.
53. RESKE, D. et al. 2003. The immunomodulatory properties of in vitro immunoglobulins are dose-dependent. Acta Neurol. Scand. 108: 267-273.